RESUMEN
Endometriosis is a common condition in reproductive age women that is defined as the presence of endometrial tissue (epithelial and/or stromal) outside the uterine corpus. While not a premalignant lesion, it is a condition with a potential for malignancy, especially in the ovaries. Notable endometriosis-associated neoplasms include clear cell carcinoma and endometrioid adenocarcinoma of the ovaries. There have been recent reports of mesonephric-like adenocarcinoma (MLA) of the ovary, a very rare neoplasm with similar morphologic and immunophenotypic characteristics as mesonephric adenocarcinoma, however, without an association with mesonephric remnants. Some of these cases have been associated with endometriosis. Here, we describe 2 cases of MLA arising directly from endometriosis. In both cases, there was evidence of endometriosis contiguous with the tumor and invasion from other sources was excluded. The immunophenotypes of both tumors were typical of mesonephric adenocarcinoma except PAX-8 was strongly positive suggesting a Mullerian origin. Molecular testing on one of the cases revealed KRAS and P53 mutations. We review published findings of MLA and associated endometriosis. This report describes the sixth and seventh reported cases of MLA associated with endometriosis and the first reported cases of MLA arising directly from endometriosis and associated with other forms of epithelial proliferation within endometriosis. These 2 cases provide potential evidence that MLA should be considered an endometriosis-associated neoplasms.
Asunto(s)
Adenocarcinoma de Células Claras , Carcinoma Endometrioide , Endometriosis , Humanos , Femenino , Carcinoma Endometrioide/patología , Mesonefro/patología , Adenocarcinoma de Células Claras/patología , Endometriosis/complicaciones , Endometriosis/patología , MutaciónRESUMEN
Ovarian combined serous borderline tumor/low-grade serous carcinomas (SBT/LGSC) and mesonephric-like adenocarcinomas (MLA) have been previously reported and the presence of identical oncogenic somatic mutations in both components supports the concept that at least some of MLAs arise from a Müllerian origin. We report 2 cases of ovarian combined SBT/LGSC and mesonephric-like lesion. Case 1 was a 70-yr-old woman presented with a liver lesion and omental carcinomatosis. Histologic examination revealed biphasic tumors in bilateral ovaries consisting of conventional SBT and invasive MLA with extraovarian spread. The right ovary also had a component of cribriform variant of SBT/noninvasive LGSC. The SBT/LGSC component was diffusely positive for Pax8, WT-1, and ER, focally positive for PR, and negative for GATA3, while the MLA component was diffusely positive for GATA3 but negative for WT-1, ER, and PR. Molecular analysis revealed a KRAS G12V mutation in both the SBT/LGSC and MLA components, indicating their clonal origin. Case 2 was a 58-yr-old woman who presented with conventional type SBT in both ovaries. In addition, the left ovarian tumor demonstrated a few areas (each <5 mm) of mesonephric-like differentiation/hyperplasia in close proximity to the serous-type epithelium, with an immunophenotype of focal GATA3 expression, luminal pattern of CD10 staining and negative WT-1, ER, and PR staining. This phenomenon has been reported in endometrioid borderline tumor but not in any serous type lesions. The findings in case 1 provide further evidence to demonstrate the clonal relationship between these morphologically and immunophenotypically distinct components. It also supports the theory that, unlike cervical mesonephric carcinomas originating from mesonephric remnants, MLAs are derived from a Müllerian-type lesion with differentiation into mesonephric lineage. The presence of a hyperplastic mesonephric-like lesion/differentiation in case 2 indicates that a precursor lesion in the same lineage with the potential to develop into MLA exists in the ovary.
Asunto(s)
Carcinoma , Cistadenocarcinoma Seroso , Neoplasias Ováricas , Femenino , Humanos , Neoplasias Ováricas/diagnóstico , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Carcinoma/patología , Mesonefro/patología , Epitelio/patología , Hiperplasia/patología , Cistadenocarcinoma Seroso/diagnóstico , Cistadenocarcinoma Seroso/genética , Cistadenocarcinoma Seroso/patologíaRESUMEN
Mesonephric-like adenocarcinoma is a relatively rare neoplasm with morphology similar to mesonephric adenocarcinoma but unassociated with mesonephric remnants. Its relatively recent description and rarity make it difficult to diagnose, but it has a high rate of distant metastasis, making distinction from endometrioid carcinoma important. Descriptions of its cytologic features are particularly limited. We describe a case of mesonephric-like adenocarcinoma diagnosed on transbronchial needle aspiration of the lung, that had been misdiagnosed as endometrioid endometrial adenocarcinoma on a prior hysterectomy. We discuss the characteristic cyto and histomorphology, immunoprofile, molecular alterations, and clinical significance of this uncommon tumor.
Asunto(s)
Adenocarcinoma/patología , Bronquios/patología , Citodiagnóstico , Neoplasias Endometriales/diagnóstico , Neoplasias Endometriales/patología , Mesonefro/patología , Biopsia con Aguja Fina , Proteínas de Unión al ADN/metabolismo , Epitelio/patología , Femenino , Humanos , Persona de Mediana Edad , Metástasis de la Neoplasia , Factor de Transcripción PAX8/metabolismo , Factores de Transcripción/metabolismoRESUMEN
Endometrial mesonephric-like carcinoma (ML-CA) is a recently recognized subtype of aggressive endometrial adenocarcinoma that is morphologically and immunophenotypically similar to mesonephric carcinoma but not typically associated with mesonephric remnants. Here, we report a case of 58-yr-old female who had a past medical history of fibroids and of irregular menstrual bleeding for ~20 yr who presented with visual disturbance. On further investigation, she was found to have a large choroidal peri-papillary tumor of the right eye. A presumptive diagnosis of choroidal melanoma was made. Right eye enucleation was performed, and microscopy revealed moderately differentiated metastatic adenocarcinoma. Further work up was advised. A uterine mass was identified on imaging followed by endometrial biopsy that showed a morphologically and immunohistochemically similar tumor to that in the eye. A hysterectomy was carried out and a malignant neoplasm with varying morphologic patterns including gland formation, solid sheets of tumor cells, cribriform, glomeruloid, spindled and papillary areas was seen. The immunohistochemical profile showed diffuse strong positivity for AE1/AE3, TTF1, P16, and vimentin. CD56, GATA3, Napsin A, and CD10 were focally positive. The neoplastic cells were negative for the following markers ER, PR, WT1, calretinin, and synaptophysin. PDL-1 was negative and mismatch repair protein was proficient. An identical KRAS mutation was detected in both the uterine corpus and ocular tumors. The findings are in keeping with a uterine mesonephric-like adenocarcinoma with an ocular metastasis. An Oncomine Focus-Mutation profile, Thermo-Fisher Scientific Inc., a 60 gene oncologic panel, performed on the ocular tumor, revealed no further mutations.
Asunto(s)
Adenocarcinoma , Neoplasias Endometriales , Neoplasias Uterinas , Adenocarcinoma/diagnóstico , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Neoplasias Endometriales/diagnóstico , Neoplasias Endometriales/genética , Neoplasias Endometriales/metabolismo , Femenino , Humanos , Mesonefro/patología , Neoplasias Uterinas/patologíaRESUMEN
La persistencia de restos derivados del mesonefros suele presentarse en las paredes laterales del cérvix de forma frecuente. En cambio, la evolución hacia una hiperplasia mesonéfrica o un carcinoma mesonéfrico es muy poco frecuente. Presentamos a una paciente de 50 años, intervenida de histerectomía por útero miomatoso, en cuya pieza quirúrgica se describe una hiperplasia mesonéfrica difusa. La presencia de restos procedentes del mesonefros o hiperplasia, constituyen en casi la totalidad de las ocasiones un hallazgo benigno que no precisa tratamiento. Es necesario conocer las características de este tipo de lesiones derivadas del mesonefros, para evitar tratamientos innecesarios
The persistence of mesonephric remnants is often present on the side walls of the cervix. However, the evolution towards mesonephric hyperplasia or mesonephric carcinoma is very rare. The case is presented of a 50-year-old female patient, who underwent hysterectomy for myomatous uterus, and in which surgical specimen was described a diffuse mesonephric hyperplasia. The presence of remains from mesonephros or hyperplasia is almost always a benign finding that does not require treatment. It is necessary to know the characteristics of this type of lesion derived from mesonephros, in order to avoid unnecessary treatments
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Conductos Mesonéfricos/patología , Mesonefro/patología , Histerectomía Vaginal/métodos , Conductos Mesonéfricos/diagnóstico por imagen , Vimentina/análisis , Biomarcadores de Tumor/análisisAsunto(s)
Cuello del Útero/patología , GTP Fosfohidrolasas/genética , Proteínas de la Membrana/genética , Lesiones Precancerosas/genética , Lesiones Precancerosas/patología , Proteínas Proto-Oncogénicas p21(ras)/genética , Adolescente , Adulto , Análisis Mutacional de ADN , Femenino , Humanos , Hiperplasia/genética , Hiperplasia/patología , Mesonefro/patología , Persona de Mediana Edad , MutaciónRESUMEN
Human papillomavirus (HPV)-negative cervical carcinomas are uncommon and typically encompass unusual histologic subtypes. Mesonephric adenocarcinoma is one such subtype. Mesonephric tumors in the female genital tract are thought to arise from Wolffian remnants, and are extremely rare tumors with widely variable morphology. Sarcomatoid dedifferentiation has been previously described in a few cases, but other forms of dedifferentiation have not been reported. Neuroendocrine carcinoma of the cervix (e.g. small cell carcinoma) is associated with HPV infection, typically HPV 18. These tumors often arise in association with a conventional epithelial component such as squamous cell carcinoma or usual-type endocervical adenocarcinoma. We describe a case of mesonephric adenocarcinoma of the uterine cervix associated with an HPV-negative high-grade neuroendocrine carcinoma at the morphologic and immunophenotypic level, for which we performed targeted massively parallel sequencing analysis of the 2 elements. Both components shared identical mutations in U2AF1 p.R156H (c.467G>A) and GATA3 p.M422fs (c.1263dupG), as well as MYCN amplification. In addition, the neuroendocrine carcinoma harbored TP53 and MST1R mutations not present in the mesonephric carcinoma. Our data suggest a clonal origin of the 2 components of this rare entity, rather than a collision tumor.
Asunto(s)
Carcinoma Neuroendocrino/genética , Factor de Transcripción GATA3/genética , Mesonefroma/genética , Factor de Empalme U2AF/genética , Neoplasias del Cuello Uterino/genética , Carcinoma Neuroendocrino/diagnóstico , Carcinoma Neuroendocrino/patología , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Mesonefroma/diagnóstico , Mesonefroma/patología , Mesonefro/patología , Persona de Mediana Edad , Análisis de Secuencia de ADN , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias del Cuello Uterino/patologíaRESUMEN
AIMS: To report a series of uterine corpus (n = 7) and ovarian (n = 5) neoplasms which we believe probably represent mesonephric adenocarcinomas based on their characteristic morphology and immunophenotype. METHODS AND RESULTS: All neoplasms exhibited a relatively constant and characteristic morphological appearance with an admixture of architectural patterns with small glands or tubules, some containing luminal eosinophilic colloid-like material, typically predominating. Solid and papillary architectures were also often present. The nuclear features were characteristic with atypical angulated clear vesicular nuclei which often exhibited overlapping. All the tumours were 'flat' negative with oestrogen receptor and progesterone receptor and all except one exhibited nuclear staining with thyroid transcription factor 1 (TTF1), which was often diffuse. All tumours exhibited wild-type staining with p53. CD10, calretinin and GATA binding protein 3 (GATA3) were positive in a variable proportion of the neoplasms. CONCLUSIONS: We believe these neoplasms to represent mesonephric adenocarcinomas which have only rarely been reported to arise in the uterine corpus and never in the ovary. We recommend they be termed mesonephric-like adenocarcinomas until their histogenesis is firmly established.
Asunto(s)
Adenocarcinoma/patología , Biomarcadores de Tumor/metabolismo , Proteínas de Unión al ADN/metabolismo , Neoplasias Ováricas/patología , Neoplasias Uterinas/patología , Adenocarcinoma/metabolismo , Adulto , Anciano , Núcleo Celular/metabolismo , Femenino , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Mesonefro/metabolismo , Mesonefro/patología , Persona de Mediana Edad , Neoplasias Ováricas/metabolismo , Estudios Retrospectivos , Factores de Transcripción , Neoplasias Uterinas/metabolismo , Útero/metabolismo , Útero/patologíaRESUMEN
PAX8 is a useful immunohistochemical marker for the diagnosis of gynecologic tract malignancies. Several studies have described PAX8 expression in a wide variety of epithelial neoplasms, including ovarian and endometrial carcinomas. The goal of this study was to evaluate PAX8 expression in various types of uterine adenocarcinomas and mesonephric proliferations. Ninety-four cases of uterine adenocarcinomas (52 endometrial endometrioid carcinomas, 21 endometrial serous carcinomas, and 21 human papillomavirus-related endocervical carcinomas), 11 cases of benign mesonephric proliferations (remnants/hyperplasia), and normal endometrial and endocervical glandular epithelium in 58 cases were studied. Immunohistochemical staining was performed with the rabbit polyclonal anti-PAX8 antibody. All adenocarcinoma groups demonstrated a high frequency of PAX8 expression but with relatively high variability in the extent of staining among different subtypes. Both serous carcinomas and endometrioid carcinomas were positive in most cases (95% and 96%, respectively), but serous carcinomas displayed a significantly higher level of expression (immunohistochemical composite scores based on combined extent and intensity of expression) compared with endometrioid carcinomas (mean immunohistochemical composite scores: 8.3 vs. 5.3, respectively; P<0.006). Endocervical adenocarcinomas also had a high frequency of PAX8 expression (86% of cases), but the level of expression was significantly less than that of endometrial adenocarcinomas (mean immunohistochemical composite scores: 2.9 vs. 5.3-8.3, respectively; P<0.004). Among benign glandular epithelia, normal endocervical glands exhibited a significantly lower level of expression compared with either normal endometrial glands or benign mesonephric proliferations (mean immunohistochemical composite scores: 2.6 vs. 6.6-11.2, respectively; P<0.0006). We conclude that PAX8 is expressed in the vast majority of uterine adenocarcinomas, including those of both endometrial and endocervical origin, and that the level of expression based on combined extent and intensity is highest in endometrial serous carcinoma and lowest in endocervical adenocarcinoma. However, the high prevalence of PAX8 expression in the various types of uterine adenocarcinomas precludes use of this marker for distinguishing these tumors. In extrauterine sites, PAX8 can serve as a useful marker for adenocarcinomas of uterine origin (also positive in the majority of ovarian carcinomas), being most sensitive for identification of endometrial adenocarcinomas (both serous and endometrioid). The sensitivity for identifying metastatic endocervical adenocarcinomas is likely less and dependent on the degree to which the significantly lower extent of expression in these tumors is maintained in metastatic sites.
Asunto(s)
Adenocarcinoma/metabolismo , Mesonefro/metabolismo , Factores de Transcripción Paired Box/metabolismo , Neoplasias Uterinas/metabolismo , Útero/metabolismo , Adenocarcinoma/patología , Biomarcadores de Tumor/metabolismo , Femenino , Humanos , Mesonefro/patología , Factor de Transcripción PAX8 , Neoplasias Uterinas/patología , Útero/patologíaAsunto(s)
Cuello del Útero/patología , Mesonefro/patología , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Adenocarcinoma de Células Claras/metabolismo , Adenocarcinoma de Células Claras/patología , Adulto , Carcinoma Endometrioide/metabolismo , Carcinoma Endometrioide/patología , Cuello del Útero/metabolismo , Cuello del Útero/cirugía , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , Diagnóstico Diferencial , Electrocirugia , Neoplasias Endometriales/metabolismo , Neoplasias Endometriales/patología , Femenino , Humanos , Hiperplasia , Queratina-7/metabolismo , Mesonefro/metabolismo , Mesonefro/cirugía , Neprilisina/metabolismo , Neoplasias del Cuello Uterino/metabolismo , Neoplasias del Cuello Uterino/patologíaRESUMEN
Cervical carcinosarcomas are rare neoplasms that aggressively progress and belong to the histological group of mixed tumors with both epithelial and mesenchymal components (malignant mixed Müllerian tumors). At diagnosis, most patients present with vaginal bleeding and a palpable cervical mass. Given the rarity of this neoplasm, there is no consensus regarding the management of these patients and should be approached on a case-by-case basis, taking into consideration the clinical and pathological features of the tumor. The authors describe a woman with mesonephric cervical carcinosarcoma and review the literature regarding these rare tumors to better understand the natural history of these neoplasms.
Asunto(s)
Carcinosarcoma/patología , Mesonefro/patología , Neoplasias del Cuello Uterino/patología , Anciano , Anciano de 80 o más Años , Femenino , HumanosRESUMEN
Mezonefric cervical cancer was more prevalent in younger women (mean age 42.2 +/- 1.2 years) with no classic predisposing factors. In most cases (62.1%) the localized stage of the disease (I, II stages) dominated. Regional metastases correlated with depth of tumor invasion (with a depth of invasion of more than 10 mm--57.8%). There was marked low expression of HER2/neu (only in 1 of 14 samples it was revealed light positive reaction. Proliferation index Ki-67 was 37.5% and the signs of mutation in the p53 gene were found in 28.4% of cases. Estimating that two thirds of patients with clear-cervical cancer revealed localized forms of the disease, and that most of the women had received the combination treatment (51.8%)--a 5-year survival rate was quite high and was 79.3%.
Asunto(s)
Adenocarcinoma de Células Claras/química , Adenocarcinoma de Células Claras/diagnóstico , Biomarcadores de Tumor/análisis , Neoplasias del Cuello Uterino/química , Neoplasias del Cuello Uterino/diagnóstico , Adenocarcinoma de Células Claras/mortalidad , Adenocarcinoma de Células Claras/patología , Adenocarcinoma de Células Claras/terapia , Adulto , Distribución por Edad , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Antígeno Ki-67/análisis , Mesonefro/patología , Prevalencia , Pronóstico , Receptor ErbB-2/análisis , Federación de Rusia/epidemiología , Análisis de Supervivencia , Neoplasias del Cuello Uterino/mortalidad , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/terapiaRESUMEN
Mesonephric adenocarcinomas are rare neoplasms that most commonly arise in the uterine cervix and exceptionally rarely in the uterine corpus. Although the morphologic features of these neoplasms are well described, there has been relatively limited investigation of the immunoprofile. We report a series of 8 mesonephric adenocarcinomas arising in the uterine cervix (7 cases) and corpus (1 case) and undertake a comprehensive immunohistochemical analysis. This includes markers that have not been investigated previously in mesonephric adenocarcinomas but that are commonly used in gynecologic pathology and may be undertaken when other, mainly Mullerian, adenocarcinomas are considered in the differential diagnosis. Linear array human papillomavirus (HPV) genotyping was also performed. Our results broadly confirm the immunohistochemical profile demonstrated in previous studies with the majority of mesonephric adenocarcinomas staining positively with CD10 (6 of 8), epithelial membrane antigen (8 of 8), vimentin (8 of 8), and calretinin (7 of 8). Estrogen receptor was positive in 2, carcinoembryonic antigen in 3, and inhibin in 4 cases. p16 was positive in 5 cases (1 diffuse and strong), despite all being HPV negative (in 1 case, there was insufficient DNA for HPV analysis). Novel findings in our study were the demonstration of nuclear positivity with PAX8 and HMGA2 in 7 cases, CA125 immunoreactivity in all 8 cases, and TTF1 and hepatocyte nuclear factor 1-ß staining in 3 cases. As PAX8, CA125, HMGA2, and hepatocyte nuclear factor 1-ß are commonly positive in a variety of Mullerian adenocarcinomas arising in the female genital tract, this may result in diagnostic confusion. All cases were WT1 negative.
Asunto(s)
Adenocarcinoma/patología , Biomarcadores de Tumor/metabolismo , Mesonefro/patología , Proteínas de Neoplasias/metabolismo , Neoplasias del Cuello Uterino/patología , Útero/patología , Adenocarcinoma/metabolismo , Adenocarcinoma/virología , Anciano , Antígeno Ca-125/metabolismo , Núcleo Celular/metabolismo , Núcleo Celular/patología , Proteínas de Unión al ADN/metabolismo , Femenino , Proteína HMGA2/metabolismo , Factor Nuclear 1-beta del Hepatocito/metabolismo , Humanos , Histerectomía , Inmunohistoquímica/métodos , Proteínas de la Membrana/metabolismo , Mesonefro/metabolismo , Mesonefro/virología , Persona de Mediana Edad , Factor de Transcripción PAX8 , Factores de Transcripción Paired Box/metabolismo , Papillomaviridae/aislamiento & purificación , Factores de Transcripción , Neoplasias del Cuello Uterino/metabolismo , Neoplasias del Cuello Uterino/virología , Útero/metabolismoRESUMEN
Mesonephric remnants of the cervix are vestiges of the embryonic mesonephric system which typically regresses during female development. Uncommonly, hyperplasia of the mesonephric remnants may occur. The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist. PAX2 encodes a transcription factor necessary in the development of the Wolffian duct system, and the protein is expressed in several tumors of mesonephric origin, including renal cell carcinoma, Wilm tumor, and nephrogenic adenoma. We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix. We demonstrated that PAX2 was strongly and diffusely expressed in mesonephric remnants (6 of 6) and in mesonephric hyperplasia (18 of 18); however, no expression was noted in mesonephric adenocarcinoma (0 of 1). PAX2 was expressed in normal endocervical glands (including tunnel clusters and Nabothian cysts) (86 of 86), lobular endocervical glandular hyperplasia (5 of 5), tubal/tuboendometrioid metaplasia (8 of 8), and cervical endometriosis (13 of 14). In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)]. Adjacent adenocarcinoma in situ, as well as cases of pure adenocarcinoma in situ (0 of 6), were also PAX2 negative. PAX2 expression in the 2 positive endocervical adenocarcinomas was patchy and weak. Most (11 of 15) stage II endometrial endometrioid adenocarcinomas lacked PAX2 expression but 1 of 10 grade 1 tumors and 3 of 5 grade 2 tumors did express PAX2. These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ. Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
Asunto(s)
Adenocarcinoma/diagnóstico , Adenoma/diagnóstico , Cuello del Útero/patología , Mesonefro/patología , Conductos Paramesonéfricos/patología , Factor de Transcripción PAX2/metabolismo , Neoplasias del Cuello Uterino/diagnóstico , Adenocarcinoma/metabolismo , Biomarcadores de Tumor , Núcleo Celular/metabolismo , Núcleo Celular/patología , Cuello del Útero/metabolismo , Diagnóstico Diferencial , Femenino , Humanos , Hiperplasia/diagnóstico , Hiperplasia/metabolismo , Inmunohistoquímica/métodos , Estadificación de Neoplasias , Lesiones Precancerosas/diagnóstico , Neoplasias del Cuello Uterino/metabolismoRESUMEN
Mesonephric remnant (MR) hyperplasia in the prostate is a rarely reported condition that is usually distinguished from prostatic adenocarcinoma by the absence of cytologic atypia as well as the absence of prostatic markers (prostate-specific antigen and prostatic acid phosphatase) expression. We report a case of prostatic MR hyperplasia with architectural and cytologic atypia in a 56-year-old man. The microscopic appearance strongly suggested malignancy, but immunohistochemistry allowed the diagnosis to be corrected. The presence of MRs in prostate tissues may be more common than appreciated or reported. Once the possibility is considered, the diagnosis is easily confirmed using immunochemistry.
Asunto(s)
Hamartoma/patología , Mesonefro/patología , Hiperplasia Prostática/patología , Neoplasias de la Próstata/patología , Biomarcadores de Tumor/metabolismo , Diagnóstico Diferencial , Hamartoma/metabolismo , Humanos , Inmunohistoquímica , Masculino , Mesonefro/metabolismo , Persona de Mediana Edad , Hiperplasia Prostática/metabolismo , Neoplasias de la Próstata/metabolismo , Coloración y EtiquetadoRESUMEN
Growth of the remnant embryonic kidney (the mesonephros), as expressed by wet weight, was more rapid in the chick embryos with experimentally induced unilateral renal agenesis compared to controls. The difference was significant between embryonic days 8-12, when the doubled weights of remnant kidneys were increased compared with the weights of paired control kidneys. The excessive growth of the mesonephros ceased on day 14, when the normal physiological regression of the embryonic kidney begins. In the definitive kidney, the metanephros, no significant differences in weights of the control vs. remnant metanephros were found on days 10-14. The characteristics of increased mesonephric growth were evaluated by determination of DNA/protein ratios in homogenates of the kidneys. Significant cellular hypertrophy was found in both the mesonephros and metanephros of the embryos with URA on day 10. Additionally, a non-significant cellular hyperplasia was also revealed in the remnant mesonephros on day 8. This gives evidence that the growth stimuli to the mesonephroi were probably strongest between days 8-10 and that they manifested in the remnant mesonephros only.
Asunto(s)
Riñón/crecimiento & desarrollo , Mesonefro/crecimiento & desarrollo , Animales , Proliferación Celular , Embrión de Pollo , Replicación del ADN , Técnicas de Cultivo de Embriones , Hiperplasia , Hipertrofia , Riñón/anomalías , Riñón/embriología , Riñón/patología , Mesonefro/patología , Factores de TiempoRESUMEN
Female adnexal tumors of probable wolffian origin (FATWO) are rare neoplasms believed to originate from mesonephric (wolffian) remnants. Rarity and variable location of FATWO make the diagnosis difficult. Although most cases follow a benign clinical course, approximately 10% of them either recur or metastasize and are thought to be resistant to chemoradiation therapy. In 2004, imatinib therapy, a tyrosine kinase inhibitor known to be effective against gastrointestinal stromal tumors, was reported to be effective also in a case of KIT-positive FATWO. However, c-kit gene mutations in FATWO have never been studied. Herein is reported the case of a 50-year-old Japanese woman with FATWO arising in the right paratubal site. The tumor had typical characteristics of FATWO in both morphology and immunohistochemistry. KIT protein was diffusely and weakly expressed, but DNA analysis revealed no mutational change in exon 9 or 11 of the c-kit gene. It is believed that accumulation of such genetic data of FATWO are essential from a therapeutic standpoint, although the present case had no mutation. In addition, the cytological features of this rare tumor are presented, which have not been described previously.